Rotigotine Patent Expiration
Rotigotine is Used for treating restless legs syndrome and Parkinson's disease symptoms with transdermal delivery of rotigotine. It was first introduced by Ucb Inc
Rotigotine Patents
Given below is the list of patents protecting Rotigotine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Neupro | US9925150 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | Mar 01, 2032 | Ucb Inc |
| Neupro | US10130589 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | Dec 22, 2030 | Ucb Inc |
| Neupro | US10350174 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | Dec 22, 2030 | Ucb Inc |
| Neupro | US8246979 | Transdermal delivery system for the administration of rotigotine | Sep 01, 2027 | Ucb Inc |
| Neupro | US8246980 | Transdermal delivery system |
Nov 27, 2025
(Expired) | Ucb Inc |
| Neupro | US8617591 | Transdermal delivery system for the administration of rotigotine |
Jul 22, 2023
(Expired) | Ucb Inc |
| Neupro | US6884434 | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
Mar 30, 2021
(Expired) | Ucb Inc |
| Neupro | US6699498 | Transdermal therapeutic systems having improved stability and their production |
Nov 27, 2020
(Expired) | Ucb Inc |
| Neupro | US7413747 | Transdermal therapeutic system for treating Parkinsonism |
Mar 18, 2019
(Expired) | Ucb Inc |
Rotigotine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rotigotine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Bioequivalence and Adhesion of a Rotigotine Patch in Healthy Subjects | Amarin Technologies S.A.U. | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |
| Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease | University Hospital, Rouen | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |